AVNS · As filed with the SEC
Avanos Medical income statement, by quarter
The statement as Avanos Medical presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
CONDENSED CONSOLIDATED INCOME STATEMENTS · USD, except per-share amounts
| USD, except per-share amounts | Q1 2026 3 months ended Mar 31, 2026 | Q4 2025† 3 months ended Dec 31, 2025 | Q3 2025 3 months ended Sep 30, 2025 | Q2 2025 3 months ended Jun 30, 2025 | Q1 2025 3 months ended Mar 31, 2025 | Q4 2024† 3 months ended Dec 31, 2024 |
|---|---|---|---|---|---|---|
| Net Sales | 182,200,000 | 180,900,000† | 177,800,000 | 175,000,000 | 167,500,000 | 179,600,000† |
| Cost of products sold | 88,000,000 | 94,900,000† | 91,800,000 | 82,900,000 | 77,700,000 | 81,600,000† |
| Gross Profit | 94,200,000 | 86,000,000† | 86,000,000 | 92,100,000 | 89,800,000 | 98,000,000† |
| Research and development | 5,200,000 | 6,100,000† | 6,000,000 | 5,800,000 | 5,400,000 | 5,700,000† |
| Selling and general expenses | 77,700,000 | 78,800,000† | 77,600,000 | 83,500,000 | 75,700,000 | 79,700,000† |
| Goodwill impairment | — | — | 0 | 77,000,000 | — | — |
| Other expense (income), net | 2,400,000 | (1,400,000)† | 2,300,000 | 300,000 | (1,600,000) | (5,600,000)† |
| Operating Income | 8,900,000 | 2,500,000† | 100,000 | (74,500,000) | 10,300,000 | (418,500,000)† |
| Interest income | 200,000 | 600,000† | 500,000 | 600,000 | 1,500,000 | 800,000† |
| Interest expense | (1,500,000) | (1,900,000)† | (1,800,000) | (2,000,000) | (2,100,000) | (2,800,000)† |
| Income before income taxes | 7,600,000 | 1,200,000† | (1,200,000) | (75,900,000) | 9,700,000 | (420,500,000)† |
| Income tax provision | (2,500,000) | (2,500,000)† | (200,000) | (900,000) | (3,100,000) | 23,500,000† |
| Loss from Continuing Operations | — | (1,300,000)† | (1,400,000) | (76,800,000) | 6,600,000 | (397,000,000)† |
| Loss from discontinued operations, net of tax | — | 0† | 0 | 0 | 0 | (300,000)† |
| Net Income | 5,100,000 | (1,300,000)† | (1,400,000) | (76,800,000) | 6,600,000 | (397,300,000)† |
| Earnings Per Share | ||||||
| Continuing operations (in dollars per share) | — | — | (0.03) | (1.66) | 0.14 | — |
| Discontinued operations (in dollars per share) | — | — | 0.00 | 0.00 | 0.00 | — |
| Basic (in dollars per share) | 0.11 | — | (0.03) | (1.66) | 0.14 | — |
| Continuing operations (in dollars per share) | — | — | (0.03) | (1.66) | 0.14 | — |
| Discontinued operations (in dollars per share) | — | — | 0.00 | 0.00 | 0.00 | — |
| Diluted (in dollars per share) | 0.11 | — | (0.03) | (1.66) | 0.14 | — |
† Derived: worked out from the filings, not stated in them. A fourth quarter is the 10-K year less the nine months in the third-quarter 10-Q; a quarter of cash flows is year to date less the prior year to date.
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.